RxDoctor Payments Data

Julianne Jackson

Medical · Mays Landing, NJNPI 1437197209

Payments from drug & device makers

$1,885in general payments, 2019–2025

Across 106 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$584
  • Kowa Pharmaceuticals America, Inc.$214
  • Boehringer Ingelheim$176
  • Lilly USA, LLC$144
  • Novo Nordisk$132
  • Merck$94
  • plus $541 from 13 others

What the payments were for

  • Food & beverage$1,84698%
  • Education$382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,885 in reported general payments places this provider in the 75th percentile of 573 medical providers in New Jersey.

See all medical providers in New Jersey

Medicare billing

Part B allowed, 2024
$36,732
Medicare patients
106
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$27,626
FarxigaDapagliflozin Propanediol16$24,535
JardianceEmpagliflozin13$16,326
Montelukast Sodium74$1,326
Atorvastatin Calcium115$1,026
Albuterol Sulfate HfaAlbuterol Sulfate17$854
Rosuvastatin Calcium50$710
Omeprazole35$539
Losartan Potassium56$524
Valsartan12$486
Propranolol Hcl12$410
FenofibrateFenofibrate Nanocrystallized13$408
SynthroidLevothyroxine Sodium13$389
Lisinopril45$367
Amlodipine Besylate48$359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$132$27,62614 claims
AstraZenecaFarxiga$584$24,53516 claims
Boehringer IngelheimJardiance$176$16,32613 claims
AbbVieSynthroid$15$38913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 573 medical providers in New Jersey.

Other medical in Mays Landing

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →